Meta-Analysis Compares Weight Loss Efficacy Across Tirzepatide, Semaglutide, and Liraglutide
A new meta-analysis compared weight loss outcomes for three GLP-1 receptor agonists: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza). The study evaluated clinical efficacy data across the three drug classes to determine comparative effectiveness for weight management. The findings provide evidence that could inform prior authorization criteria, formulary placement, and medical policy for obesity treatment in Medicaid managed care plans. Many state Medicaid programs have restricted or excluded coverage of anti-obesity medications due to cost, making comparative effectiveness data particularly relevant for coverage and utilization management decisions.
Comparative effectiveness data on GLP-1 medications directly impacts formulary design, prior authorization protocols, and medical policy for obesity treatment coverage in Medicaid managed care plans facing mounting utilization and cost pressure.
Pharmacy · Managed Care
You might also like